A temporary regulation to manage an impending shortage due to extraordinary prescribing patterns of chloroquines observed during early phase of COVID-19 epidemic
Abstract
Background: Chloroquine and hydroxychloroquine (C/HC) received considerable international media attention due to anticipated treatment effect in COVID-19. This led to increased prescriptions threatening to generate product shortages for patients prescribed within approved indications.
We evaluated effects of a temporary regulation mandating pharmacies to only dispense C/HC prescribed by physicians with defined specialties.
Methods: Data from Region Stockholm, which include 2.4 out of 10 million Sweden’s population, were used. Weekly time trends of prescriptions and requisitions of C/HC by prescriber’s workplace during January to April 2020 were followed.
Results: Numbers of unique individuals with filled prescriptions of chloroquine increased tenfold and of hydroxychloroquine more than threefold from January to March. In the first week of April, filled prescriptions of C/HC dropped. In the later weeks of April, the number of filled prescriptions was back at similar levels as before the SARS-CoV-2 outbreak.
During January and February, specialists in rheumatology accounted for 686 out of all 979 prescriptions dispensed (70.1%) of C/HC. In March, a large proportion of prescriptions dispensed were from specialists not usually prescribing C/HC, and rheumatology accounted for 628 out of all 1,639 prescriptions (38.3%). In April, specialists in rheumatology accounted for 386 out of all 641 prescriptions dispensed (60.0%).
Conclusion: After an observed increase in prescriptions of C/HC, a temporary regulation was introduced on 2nd April 2020 to reduce prescriptions from specialists not usually prescribing C/HC to avoid shortages for patients within approved indications. Subsequently, dispensed prescriptions decreased from April and remained at pre-COVID-19 levels thereafter.
Downloads
References
2. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020;57:279–83. doi: 10.1016/j.jcrc.2020.03.005
3. Läkemedelsverkets föreskrifter (HSLF - FS 2020:11) om tillfälliga begränsningar av förskrivning och utlämnande av vissa läkemedel. Available from: https://www.lakemedelsverket.se/sv/lagar-och-regler/foreskrifter/2020-11 [cited 23 June 2029].
4. Läkemedelsverket vill se begränsad användning av malarialäkemedel. Lakartidningen.se 2020-04-03. Available from: https://lakartidningen.se/aktuellt/nyheter/2020/04/lakemedelsverket-vill-se-begransad-anvandning-av-malarialakemedel/ [cited 29 June 2023].
5. Expediering av klorokinrecept begränsas. Svenskfarmaci.se 2020-04-02. Available from: https://www.svenskfarmaci.se/2020/04/02/expediering-av-klorokinrecept-begransas/ [cited 19 January 2023].
6. Nu begränsas förskrivning av klorokin i Sverige. Läkemedelsvarlden.se 2020-04-02. Available from: https://www.lakemedelsvarlden.se/nu-begransas-forskrivning-av-klorokin-i-sverige/ [cited 29 June 2023].
7. Shehab N, Lovegrove M, Budnitz DS. US hydroxychloroquine, chloroquine, and azithromycin outpatient prescription trends, October 2019 through March 2020. JAMA Inter Med. 2020;180:1384–6. doi: 10.1001/jamainternmed.2020.2594
8. Bull-Otterson L, Gray EB, Budnitz DS, Strosnider HM, Schieber LZ, Courtney J, et al. Hydroxychloroquine and chloroquine prescribing patterns by provider specialty following initial reports of potential benefit for COVID-19 treatment – United States, January–June 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1210–5. doi: 10.15585/mmwr.mm6935a4
9. Schaffer AL, Henry D, Zoega H, Elliott JH, Pearson SA. Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in Australia. PLoS One. 2022;17:e0269482. doi: 10.1371/journal.pone.0269482.
10. Pharmac. New Zealand. COVID-19: hydroxychloroquine. Restricting access. Publications and resources. 2020. Available from: https://pharmac.govt.nz/news-and-resources/covid19/covid-19-hydroxychloroquine/ [cited 15 June 2023].
11. Duffy E, Arroll N, Beasley R, Hills T. Regulatory action to protect access to hydroxychloroquine for approved rheumatic indications during COVID-19 in New Zealand. Arthritis Rheumatol. 2021;73:896–7. doi: 10.1002/art.41643.
12. No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. Recovertrial.net 05-06-2020. Available from: https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19 [cited 29 June 2023].
13. RECOVERY Collaborative Group; Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;383:2030–40. doi: 10.1056/NEJMoa2022926.
14. Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). Hydroxychloroquin – Sicherstellung der Versorgung von chronisch kranken Patientinnen und Patienten in den zugelassenen Indikationen. Arzneimittelzulassung 03 April 2020. Available from: https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Zulassung/amInformationen/Lieferengpaesse/Off_Label_Use_Hydroxychloroquin.pdf;jsessionid=E5D67A84E2CE9802068513819F4E2FA8.internet271?__blob=publicationFile [cited 15 June 2023].
15. Enners S, Gradl G, Kieble M, Böhm M, Laufs U, Schulz M. Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave. Pharmacoepidemiol Drug Saf. 2021;30:1493–503. doi: 10.1002/pds.5324
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright of their work, with first publication rights granted to Upsala Medical Society. Read the full Copyright- and Licensing Statement.
